Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 653-661 |
| Number of pages | 9 |
| Journal | Liver International |
| Volume | 37 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 1 2017 |
Fingerprint
Keywords
- cirrhosis
- elderly
- genotype 1
- hepatitis C
- simeprevir
- sofosbuvir
Cite this
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. / Pellicelli, A. M.; Palitti, V. Pace; Vignally, P.; Ceccherini-Silberstein, F.; Siciliano, M.; Giannelli, V.; Moretti, A.; Tarquini, P.; Scifo, G.; Messina, V.; Ascione, A.; Izzi, A.; Marignani, M.; D'Ambrosio, C.; Fondacaro, L.; Ettorre, G. M.; Ialongo, P.; Sacco, R.; Perno, C. F.; Barbarini, G.; Group, CLEO.
In: Liver International, Vol. 37, No. 5, 01.05.2017, p. 653-661.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study
AU - Pellicelli, A. M.
AU - Palitti, V. Pace
AU - Vignally, P.
AU - Ceccherini-Silberstein, F.
AU - Siciliano, M.
AU - Giannelli, V.
AU - Moretti, A.
AU - Tarquini, P.
AU - Scifo, G.
AU - Messina, V.
AU - Ascione, A.
AU - Izzi, A.
AU - Marignani, M.
AU - D'Ambrosio, C.
AU - Fondacaro, L.
AU - Ettorre, G. M.
AU - Ialongo, P.
AU - Sacco, R.
AU - Perno, C. F.
AU - Barbarini, G.
AU - Group, CLEO
N1 - LR: 20170428; CI: (c) 2016; JID: 101160857; OTO: NOTNLM; 2016/03/24 00:00 [received]; 2016/10/21 00:00 [accepted]; 2016/10/27 06:00 [pubmed]; 2016/10/27 06:00 [medline]; 2016/10/27 06:00 [entrez]; ppublish
PY - 2017/5/1
Y1 - 2017/5/1
N2 - BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P
AB - BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P
KW - cirrhosis
KW - elderly
KW - genotype 1
KW - hepatitis C
KW - simeprevir
KW - sofosbuvir
U2 - 10.1111/liv.13288 [doi]
DO - 10.1111/liv.13288 [doi]
M3 - Article
VL - 37
SP - 653
EP - 661
JO - Liver International
JF - Liver International
SN - 1478-3223
IS - 5
ER -